Combining D,L‐α‐difluoromethylornithine with [³H] thymidine increases killing of rat gliosarcoma cells in vitro

Abstract

SUMMARY The present studies were done to test the hypothesis that the cytostasis caused by D,L-a-difluoromethylornithine (DFMO) would enhance cellular retention of treatments (4 days [3H] thymidine followed by DFMO) had only 6 x lo3 CFC, but the group with simultaneous treatments (DFMO added on day 0 with the [3Hl thymidine) had too few CFC remaining by day 8 to measure accurately. In the group given [3H3 thymidine and DFMO sequentially, retention of [3HJ thymidine was enhanced, but in the group given DFMO simultaneously there was almost total retention as well as increased initial uptake of [3H] thymidine. These studies suggest that combining DFMO with short-range radioemitters may be a useful approach to brain tumor therapy.